3-Methyl-acetoxy-cyclopentan | 7285-41-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Methyl-acetoxy-cyclopentan
• 英文别名: 3-Methylcyclopentyl acetate；(3-methylcyclopentyl) acetate
• CAS: 7285-41-8；7285-42-9；24070-70-0
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: MCSJGRXOSPWTBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(3-甲基环戊基)乙酮 生成 3-Methyl-acetoxy-cyclopentan
  参考文献：
  名称：

  Granger; Boussinesq; Girard, Bulletin de la Societe Chimique de France, 1969, vol. 8, p. 2806 - 2812

  摘要：

  DOI：

文献信息

• Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
  申请人：White E. Ronald

  公开号：US20070021351A1

  公开（公告）日：2007-01-25

  Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating activity of HCV protease, in which liver to plasma concentration ratio of the compound ranges from about 2:1 to about 10:1.

  提供了包括至少一种从本文中定义的I到XXVI式化合物组中选择的化合物的组合物和治疗组合，以及治疗、预防或改善丙型肝炎的一个或多个症状的方法，治疗与HCV病毒相关的疾病，调节HCV蛋白酶活性，其中化合物的肝脏到血浆浓度比范围约为2:1至约为10:1。
• Pharmaceutical formulations and methods of treatment using the same
  申请人：Malcolm A. Bruce

  公开号：US20070010431A1

  公开（公告）日：2007-01-11

  Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

  含有本文中的至少一种I-XXVI式化合物和至少一种表面活性剂的制药配方。 制剂中还可以包括药用可接受的载体和辅料。 本发明的制剂适用于单剂量使用。
• Solvent-free acetylation and tetrahydropyranylation of alcohols catalyzed by recyclable sulfonated ordered nanostructured carbon
  作者：Daryoush Zareyee、Parastoo Alizadeh、Mohammad Ghandali、Mohammad Khalilzadeh

  DOI：10.2478/s11696-013-0369-x

  日期：2013.1.1

  Rapid and practical green acetylation and tetrahydropyranylation routes of structurally diverse alcohols and phenols were applied under solvent-free reaction conditions providing excellent yields, using catalytic amounts of environmentally friendly sulfonated ordered nanoporous carbon (CMK-5-SO3H). Non-toxic nature of the catalyst, its easy handling, recovery and reusability, and the absence of any solvent characterize the presented procedures as efficient methods. These procedures provide methods for the separation of the product by simple filtration.

  在无溶剂反应条件下，利用环境友好的磺酸化有序纳米多孔碳（CMK-5-SO3H）催化剂，快速且实用地对结构多样的醇和酚进行绿色乙酰化和四氢吡喃基化反应，获得优异的产率。催化剂的无毒性、易于处理、回收和重复使用，以及无溶剂的特性将所提出的方法描述为高效的方法。这些方法提供了通过简单过滤分离产物的途径。

• Highly efficient solvent-free acetylation of alcohols with acetic anhydride catalyzed by recyclable sulfonic acid catalyst (SBA-15–Ph–Pr–SO₃H) — An environmentally benign method
  作者：Daryoush Zareyee、Abdollah Razaghi Ghadikolaee、Mohammad A. Khalilzadeh

  DOI：10.1139/v2012-018

  日期：2012.5

  The catalytic activity of highly thermal stable, hydrophobic, and complete heterogeneous propylsulfonic acid functionalized nanostructured SBA-15 for excellent acetylation of alcohols and phenols with acetic anhydride at ambient temperature in solvent-free conditions was examined under environmentally benign reaction conditions. The salient features of this protocol are the absence of solvent, a green experimental procedure, and simple reusability of the catalyst (at least five reaction cycles).

  高热稳定性、疏水性和完全异相丙基磺酸功能化纳米结构SBA-15的催化活性被在环境友好反应条件下检验，该条件下在无溶剂条件下使用乙酸酐对醇和酚进行乙酰化，在常温下进行。该方案的显著特点是无溶剂、绿色实验程序以及催化剂的简单可重复使用（至少五个反应循环）。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。